Arcutis Biotherapeutics, Inc.

WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units The post Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) appeared first on Arcutis Biotherapeutics.

WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24 The post Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference appeared first on Arcutis Biotherapeutics.

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units The post Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) appeared first on Arcutis Biotherapeutics.

Continued strong ZORYVE ® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company raising 2026 full-year net product sales guidance to $525 million–$540 million Received The post Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update appeared first on Arcutis Biotherapeutics.

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher “Chris” Peetz has been appointed to the Arcutis The post Arcutis Expands Board of Directors with Appointment of Chris Peetz appeared first on Arcutis Biotherapeutics.

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results The post Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 appeared first on Arcutis Biotherapeutics.

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study 1 million children under the age of 2 are treated topically for The post FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months appeared first on Arcutis Biotherapeutics.

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 61,000 restricted stock units The post Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) appeared first on Arcutis Biotherapeutics.

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals with independent, board-certified dermatologists through a streamlined digital experience for The post Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications appeared first on Arcutis Biotherapeutics.

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use Seventh FDA approval for ZORYVE in The post FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 appeared first on Arcutis Biotherapeutics.